首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 醫療設備 > 可拋式醫學設備 > 預填充注射器:全球市場預測(2011∼2021年)
產業/市場分類
醫療設備 (4528)
內視鏡檢查設備 (158)
分子呈像/呈影劑 (28)
心血管設備 (335)
可拋式醫學設備 (76)
核子醫學 (80)
病患監測 (382)
眼科設備 (102)
傷口護理 (159)
超音波 (54)
齒科設備 (174)
導管 (232)
整形外科 (335)
醫學影像診斷 (414)
體外診斷設備 (476)
CT/MRI/X光 (172)
e保健 (321)
市場調查報告書

預填充注射器:全球市場預測(2011∼2021年)

Pre-Filled Syringes: World Market Outlook 2011-2021

出版商 Visiongain
出版日期 2011年06月 商品編碼 206673
內容資訊 英文 197 Pages
價格
US $ 2331 PDF by E-mail (Single User License)
US $ 4663 PDF by E-mail (Departmental License)
US $ 7772 PDF by E-mail (Site License)
US $ 10882 PDF by E-mail (Global Site License)


預填充注射器:全球市場預測(2011∼2021年) 是由出版商Visiongain在2011年06月所出版的。 這份英文市場調查報告書包含197 Pages 價格從美金2331起跳。

簡介

本報告提供全球預填充注射器市場相關調查分析，市場收益預測，成長率，市場佔有率，技術趨勢，到2021年為止的市場的機會與課題等資料彙整，為您概述為以下內容。

第1章 摘要整理

第2章 預填充注射器的簡介

  • 預填充注射器市場
    • 市場概要
    • 越來越受關注的領域
    • 預填充注射器的普及
    • 現狀
  • 注射器技術的簡介
    • 歷史的趨勢
  • 預填充注射器的設計和結構
    • 預填充注射器的組成零件
    • 矽和生化科技產品
    • 材料選擇:玻璃或塑膠
    • 注射器的操作:手動和機器
    • 醫藥品開發:萃取，溶出及製造殘渣
    • 醫藥品開發:給藥系統的功能檢驗
  • 預填充注射器的便利性
  • 針頭刺傷與預填充注射器的動機
    • 血源性病原體與針頭刺傷
    • 嚴重的健康問題
  • 注入型給藥系統

第3章 全球預填充注射器技術市場:2011∼2021年

  • 全球預填充注射器市場:2010年
  • 預填充注射器的成長市場
    • 預填充注射器單位:2010∼2015年
    • 預填充注射器單位:2016∼2021年
    • 手動系統與自動注射銷售額預測:2010∼2015年
    • 手動系統與自動注射銷售額預測:2016∼2021年
    • 其他的預填充注射器系統銷售額預測:2010∼2015年
    • 其他的預填充注射器系統銷售額預測:2016∼2021年
    • 摘要
  • 預填充注射器的主要市場:2010∼2021年
    • 美國
    • 日本
    • 歐洲
    • 新興經濟
    • 中國
    • 印度
  • 摘要

第4章 全球預填充注射器和相關技術市場

  • 提供發展機會的治療領域
  • 生物製品和疫苗的開發促進2011∼2021年預填充注射器市場
  • 生物藥品市場的腫瘤部門:2010年
  • 預填充注射器藥物市場:結論

第5章 上市的主要的預填充注射器產品

  • 簡介
  • 胰島素和抗糖尿病藥
  • Byetta/Exenatide LAR:革命性的非胰島素藥劑
  • 預填充注射器的主要的生化科技產品
  • 其他

第6章 預填充注射器市場主要企業

  • 簡介
  • Becton, Dickinson and Company (BD)
  • Vetter Pharma-Fertigung
  • SCHOTT
  • Abbott Laboratories
  • Ypsomed
  • Gerresheimer
  • MGlas (MG)

第7章 預填充注射器產業及影響市場因素分析

  • 簡介
  • 商業的促進因素
  • 商業的阻礙要素
  • 新興趨勢與市場的機會
  • 市場面臨的相關課題
  • 結論

第8章 研究的意見

第9章 研究分析的結論

圖表

目錄

Abstract

How will the pre-filled syringes market develop this decade? Our new report shows you potential revenues to 2021 for that technology and its applications, discussing opportunities and prospects.

Our report covers pre-filled syringes in therapeutic applications: devices and drugs. Through our research and analysis we aim to save you time and help in your decisions.

You will find potential revenues for pre-filled syringe technologies at total world, submarket and national levels to 2021. What technologies and applications will expand that market? You will find predictions and answers in our report, including forecasted sales by unit.

We forecast revenues for pre-filled syringe devices, pen systems and autoinjectors. You will see how those products are changing the market and where technologies are heading.

You will also discover commercial prospects for pre-filled applications, including forecasted revenues for leading injectable drugs and their product classes:

  • Monoclonal antibodies
  • Insulins
  • Erythropoietin products
  • Interferons
  • Granular-colony stimulating factors (G-CSF)
  • Recombinant coagulation factors
  • Vaccines
  • Biosimilars.

In particular, you will find discussions of Abbott Laboratories, Becton, Dickinson and Company, Vetter Pharma-Fertigung, SCHOTT, Ypsomed, Gerresheimer and MGlas.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

You will find revenue forecasts, growth rates, market shares, a SWOT/STEP review, opinions from our survey and discussions of technologies and companies. We provide 120 tables and charts and three research interviews (shown in the accompanying lists).

Pre-Filled Syringes: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

  • You will discover revenue forecasts to 2021 for the world pre-filled syringes market and its main components, seeing where revenue growth will occur
  • You will see a forecast of pre-filled syringe unit sales at world level
  • You will find revenue predictions to 2021 for technologies, with discussions
  • You will discover revenue forecasts to 2021 for injectable drug classes
  • You will receive revenue forecasts to 2021 for leading injectable drugs - Lantus, Novorapid, Humalog, Humira, Enbrel, Neulasta, Avonex, Rebif and others
  • You will find revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India - seeing growth trends
  • You will assess leading companies for pre-filled syringes, analysing their activities, R&D and commercial outlooks
  • You will examine established and emerging pre-filled drug technologies, seeing where the industry is heading
  • You will investigate competition and opportunities influencing the industry and market from 2011 onwards
  • You will see what will stimulate and restrain the industry and market from 2011
  • You will analyse opportunities and challenges for established companies and those seeking to enter the pre-filled syringe market
  • You will receive three interviews with authorities on pre-filled syringe technologies.

That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions in the pre-filled syringes industry and market, aiming to benefit your work.

Order our report now to gain industry and market analysis for pre-filled syringe technologies

Our report is for everybody interested in market analysis, product development, sales and marketing for injected drug delivery systems and injectable drugs. You will find predictions and answers. Don' t miss out - please order our report now

Table of Contents

1. Executive Summary

  • 1.1. Pre-Filled Syringes Market Review
  • 1.2. Aims, Scope and Format of the Report
  • 1.3. Research and Analysis Methods

2. Introduction to Pre-Filled Syringes

  • 2.1. The Pre-Filled Syringe Market
    • 2.1.1. Market Overview
    • 2.1.2. An Increasingly Alluring Sector
    • 2.1.3. Greater Prevalence of Pre-Filled Syringes
    • 2.1.4. Pre-Filled Syringes: The Current Situation
  • 2.2. Introduction to Syringe Technology
    • 2.2.1. A Brief Historical Perspective
  • 2.3. The Design and Construction of Pre-Filled Syringes
    • 2.3.1. Pre-Filled Syringe Components
    • 2.3.2. Silicone and Biotechnology Products
    • 2.3.3. Material Choice: Glass or Plastic?
    • 2.3.4. Syringe Operation: Manual vs. Mechanical
    • 2.3.5. Pharmaceutical Development: Extractables, Leachables and Manufacturing Residuals
    • 2.3.6. Pharmaceutical Development: Functional Testing of Delivery Systems
  • 2.4. Pre-Filled Syringes Offer Convenience over Alternatives
    • 2.4.1. Pre-Filled Syringes for Lyophilized Drugs
  • 2.5. Needle Stick Injuries and the Drive Towards Pre-Filled Syringes
    • 2.5.1. Blood-Borne Pathogens and Needle Stick Injury
    • 2.5.2. Accidental Needle Stick Injuries: a Serious Healthcare Problem
  • 2.6. Injection Delivery Devices
    • 2.6.1. Pen Injectors
    • 2.6.2. Insulin Pens
    • 2.6.3. Auto-Injectors
    • 2.6.4. Needle-Free Injectors
    • 2.6.5. Selection of Injection Devices

3. The World Pre-Filled Syringes Technology Market, 2011-2021

  • 3.1. The World Pre-Filled Syringes Market in 2010
  • 3.2. Growing Market for Pre-Filled Syringes
    • 3.2.1. Sales Forecast for Pre-Filled Syringe Units, 2010-2015
    • 3.2.2. Sales Forecast for Pre-Filled Syringe Units, 2016-2021
    • 3.2.3. Sales Forecast for Pen Systems and Autoinjectors Market, 2010-2015
    • 3.2.4. Sales Forecast for Pen Systems and Autoinjectors Market, 2016-2021
    • 3.2.5. Sales Forecast for Other Pre-Filled Syringe Systems Market, 2010-2015
    • 3.2.6. Sales Forecast for Other Pre-Filled Syringe Systems Market, 2016-2021
    • 3.2.7. Sales Forecast for Total Pre-Filled Syringes Market, 2010-2015
    • 3.2.8. Sales Forecast for Total Pre-Filled Syringes Market, 2016-2021
    • 3.2.9. Summary: Overall World Pre-Filled Syringes Market, 2010-2021
  • 3.3. Leading National Markets for Pre-Filled Syringes, 2010-2021
    • 3.3.1. The US Pre-Filled Syringe Market, 2010-2021
    • 3.3.2. The Japanese Pre-Filled Syringe Market, 2010-2021
    • 3.3.3. The Leading European Pre-Filled Syringe Markets, 2010-2021
    • 3.3.4. Emerging-Economy Pre-Filled Syringe Markets
    • 3.3.5. The Chinese Pre-Filled Syringe Market, 2010-2021
    • 3.3.6. The Indian Pre-Filled Syringe Market, 2010-2021
  • 3.4. Summary of National Market Forecasts

4. Worldwide Market for Pre-Filled Syringes and Related Technology

  • 4.1. Therapeutic Areas Offering Growth Opportunities
  • 4.2. Development of Biologics and Vaccines Will Drive the Pre-Filled Syringes Market from 2011-2021
  • 4.3. The Leading Sectors of Biological Drugs Market, 2010
    • 4.3.1. Monoclonal Antibodies Currently Lead the Biologics Market
      • 4.3.1.1. Long-Term Prospects for Monoclonal Antibodies and Implications for the Pre-Filled Syringes Market
    • 4.3.2. The Human Insulins Class Will Exhibit Strong Growth
    • 4.3.3. Erythropoietin Products - How Will Reported Safety Affect Sales?
      • 4.3.3.1. Erythropoietin Products Forecast, 2011-2021
    • 4.3.4. The Interferons Class will Show an Increase in Revenues from 2011-2015
      • 4.3.4.1. Long-Term Forecast for the Interferons Class
    • 4.3.5. Granular-Colony Stimulating Factors (G-CSF) Forecast, 2011-2021
    • 4.3.6. Recombinant Coagulation Factors Will Show Steady Growth
    • 4.3.7. Other Therapeutic Proteins
    • 4.3.8. The Biosimilars Market, 2010
      • 4.3.8.1. Forecast for the World Biosimilars Market, 2011-2021
    • 4.3.9. Forecast for the Vaccines Market, 2011-2021
  • 4.4. The Pre-Filled Syringe Drug Market: Conclusions

5. Leading Pre-Filled Syringe Products on the Market

  • 5.1. Introduction
  • 5.2. Insulins and Antidiabetic Agents
    • 5.2.1. Leading Human Insulins and Analogues
      • 5.2.1.1. Lantus
      • 5.2.1.2. Humalog
      • 5.2.1.3. Novorapid
      • 5.2.1.4. NovoMix/NovoLog
      • 5.2.1.5. Levemir
      • 5.2.1.6. Actraphane HM
  • 5.3. Byetta/Exenatide LAR: Non-Insulin Revolutionary Injectable
    • 5.3.1. Byetta' s Strengths
    • 5.3.2. Restraints on Byetta
  • 5.4. Leading Biotech Products in Pre-Filled Syringe Format
    • 5.4.1. Humira
      • 5.4.1.1. Humira - Leading Biotech Drug
      • 5.4.1.2. Humira Market Forecast, 2011-2015
      • 5.4.1.3. Long-Term Prospects for Humira
    • 5.4.2. Enbrel
      • 5.4.2.1. Amgen Continues to Benefit from Enbrel Sales
      • 5.4.2.2. Enbrel Sales Will Show an Initial Increase
      • 5.4.2.3. Study Eases Fears of TNF Blocker Cancer Risk
      • 5.4.2.4. New Enbrel Delivery System
      • 5.4.2.5. Enbrel Lifecycle Management
      • 5.4.2.6. Sales of Enbrel Will Eventually Decline
      • 5.4.2.7. Enbrel Faces Competition from Several Other Biotech Drugs
      • 5.4.2.8. Competition from Biosimilars?
    • 5.4.3. Neulasta
      • 5.4.3.1. Neulasta Sales Forecast, 2011-2021
  • 5.5. Other Pre-Filled Drugs on the Market
    • 5.5.1. Avonex
      • 5.5.1.1. Avonex Market Forecast, 2011-2021
      • 5.5.1.2. Avonex Faces Competition from New Oral MS Drugs
    • 5.5.2. Rebif
      • 5.5.2.1. Rebiject II
      • 5.5.2.2. RebiSmart
      • 5.5.2.3. Rebif Sales Forecast, 2011-2015
      • 5.5.2.4. Rebif Sales Forecast, 2016-2021

6. Leading Companies in the Pre-Filled Syringe Field

  • 6.1. Introduction
  • 6.2. Becton, Dickinson and Company (BD)
    • 6.2.1. Overview
    • 6.2.2. Global Presence
    • 6.2.3. Distribution
    • 6.2.4. Focus on Parenteral and Biomaterial Technologies
    • 6.2.5. Products
      • 6.2.5.1. BD Hypak SCF Syringe Systems
      • 6.2.5.2. BD Sterifill SCF Syringe Systems
      • 6.2.5.3. Self-Injection Systems
        • 6.2.5.3.1. BD Physioject Disposable AutoInjector
        • 6.2.5.3.2. BD MicroInfusor Automatic Injection System
        • 6.2.5.3.3. BD Liquid Dry Injector Disposable Pen Injector
        • 6.2.5.3.4. BD Pens
      • 6.2.5.4. Detachable and Integrated Safety Systems
      • 6.2.5.5. BD Soluvia Pre-Fillable Microinjection System
      • 6.2.5.6. BD Uniject SCF: Auto-Disable Injection System
    • 6.2.6. R&D
    • 6.2.7. Revenues
  • 6.3. Vetter Pharma-Fertigung
    • 6.3.1. Overview
    • 6.3.2. Global Presence
    • 6.3.3. Business Interests
      • 6.3.3.1. Vetter Development Service
      • 6.3.3.2. Vetter Commercial Manufacturing
      • 6.3.3.3. Vetter Solutions
    • 6.3.4. Capabilities
    • 6.3.5. R&D
    • 6.3.6. Product Focus
      • 6.3.6.1. Dual-Chamber Technology
      • 6.3.6.2. Single-Chamber Syringes and Cartridges
    • 6.3.7. Future Outlook
  • 6.4. SCHOTT
    • 6.4.1. Overview
    • 6.4.2. Global Presence
    • 6.4.3. SCHOTT' s Pharmaceutical Systems
    • 6.4.4. SCHOTT' s Pharmaceutical Packaging Business Segment
    • 6.4.5. Products: Pre-Fillable Polymer Syringes
      • 6.4.5.1. SCHOTT TopPac Pre-Fillable Syringes
      • 6.4.5.2. SCHOTT InJentle: Innovative Staked Needle Syringe
    • 6.4.6. Revenues
  • 6.5. Abbott Laboratories
    • 6.5.1. Overview
    • 6.5.2. Market Areas and Products
    • 6.5.3. Pre-Filled Syringe Products: Humira
    • 6.5.4. Abbott' s Other Syringe Products
      • 6.5.4.1. Abbott Abboject
      • 6.5.4.2. Abbott LifeShield
      • 6.5.4.3. Abbott Ansyr
      • 6.5.4.4. Abbott Carpuject Injector
    • 6.5.5. Revenues and Growth
  • 6.6. Ypsomed
    • 6.6.1. Overview
    • 6.6.2. Global Presence
    • 6.6.3. Products
      • 6.6.3.1. Insulin Pen Injectors
      • 6.6.3.2. Pen Injectors for Other Indications
      • 6.6.3.3. Monodose Pens for Dual-Chamber Cartridges
      • 6.6.3.4. Disposable Auto-Injectors
      • 6.6.3.5. Standard Pen Needles Penfine and Clickfine
      • 6.6.3.6. Safety Pen Needle Clickfine AutoProtect
    • 6.6.4. R&D
    • 6.6.5. Revenues and Growth
    • 6.6.6. Future Outlook
  • 6.7. Gerresheimer
    • 6.7.1. Overview
    • 6.7.2. Business Operations
    • 6.7.3. Locations
    • 6.7.4. Gerresheiemer' s Tubular Glass Division
    • 6.7.5. Syringe Systems
      • 6.7.5.1. Technology Centre for Syringe Systems
      • 6.7.5.2. Technical Competence Centre for Plastic Products
    • 6.7.6. Revenues
    • 6.7.7. R&D
    • 6.7.8. Outlook
  • 6.8. MGlas (MG)
    • 6.8.1. Overview
    • 6.8.2. Products
      • 6.8.2.1. Pre-Fillable Syringes/Cartridges/Vials
      • 6.8.2.2. MG Innovative Needles

7. Analysis of Forces Influencing the Pre-Filled Syringes Industry and Market

  • 7.1. Introduction
  • 7.2. Commercial Drivers of the Pre-Filled Syringes Market
    • 7.2.1. Cost Savings - a Powerful Motivator?
    • 7.2.2. Glass Pre-Fillable Syringes
    • 7.2.3. Plastic Pre-Fillable Syringes
    • 7.2.4. Convenience and Safety Issues
    • 7.2.5. Cost Efficiencies
    • 7.2.6. Product Differentiation and Customization
    • 7.2.7. Reimbursement
  • 7.3. Commercial Restraints for the Pre-Filled Syringes Market
    • 7.3.1. Pre-Filled Syringe Systems Have Limitations
    • 7.3.2. Patients Prefer Pills
  • 7.4. Emerging Trends and Opportunities in the Pre-Filled Syringes Market: Opportunity Analysis
  • 7.5. Challenges Facing the Pre-Filled Syringes Market
    • 7.5.1. Needle Stick Safety and Prevention Laws
      • 7.5.1.1. Compliance with Needle Stick Safety and Prevention Laws
      • 7.5.1.2. Main Findings Leading to the Legislation
      • 7.5.1.3. Increasing Exposure to Blood-Borne Pathogens
      • 7.5.1.4. OSHA 1991 Regulation Standard
      • 7.5.1.5. Estimated Needle Stick and Other Percutaneous Injuries Occurring Annually in the US
      • 7.5.1.6. Newer Engineering Controls and Safer Medical Devices
      • 7.5.1.7. CDC Estimates 80% of Sharps Injuries Are Preventable
      • 7.5.1.8. OSHA 200 Log Surveillance System
      • 7.5.1.9. Training and Education
      • 7.5.1.10. Summary of Regulatory and Legislative Requirements
    • 7.5.2. State-Level OSHA Plans and Federal Legislation
    • 7.5.3. BPS Enforcement by OSHA
    • 7.5.4. Laws in Other International Markets
    • 7.5.5. EU on the Threshold of New Laws to Tackle Needle Stick Injuries
    • 7.5.6. High Entry Barriers, Few Suppliers
    • 7.5.7. Product Stability a Major Concern
      • 7.5.7.1. Leachables and Safety
      • 7.5.7.2. Compatibility between Drug Product and Pre-Filled Syringes
      • 7.5.7.3. Eprex and Leaching
      • 7.5.7.4. Protein Aggregation Related to Leached Tungsten
      • 7.5.7.5. Protein Aggregation Related to Silicone Oil
    • 7.5.8. Product Stability and Quality Assurance Programme
      • 7.5.8.1. A Paediatric H1N1 Vaccine Withdrawn from the Market
      • 7.5.8.2. Voluntary Withdrawal of Five Lots of Flu Vaccine
      • 7.5.8.3. Shelf Life of Some H1N1 Vaccine Batches Apparently Changed
      • 7.5.8.4. Contamination Problems with Leachables in Pre-Fillable Syringes
      • 7.5.8.5. West and Daikyo Offer Syringe Systems to Minimise Leaching
      • 7.5.8.6. SCHOTT AG Launched InJentle Syringe to Improve Drug Stability
  • 7.6. Conclusions

8. Opinions from Our Survey

  • 8.1. Interview 1: Dr Phil Lever, Commercial Director, Cambridge Consultants, Cambridge, UK
    • 8.1.1. Current Market Worth for Pre-Filled Syringes
    • 8.1.2. Key Unmet Needs
    • 8.1.3. Research and Development
    • 8.1.4. Problems with the Current Use of Pre-Filled Syringes
    • 8.1.5. Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
    • 8.1.6. Drawbacks of Pre-Filled Syringes
    • 8.1.7. Key Challenges: Technologies and Strategies for the Development of Pre-Filled Devices
    • 8.1.8. Complexities for Making New Pre-Filled Syringes
    • 8.1.9. Preferred Component Materials, Surface Treatments and Filling Processes
    • 8.1.10. Technologies, Developments and R&D
    • 8.1.11. Main Therapeutic Areas Offering Growth Opportunities
    • 8.1.12. The Future of PFS over the Next 10-15 Years
    • 8.1.13. Main Threats Facing the PFS Industry
    • 8.1.14. Novel Technology/Developments
    • 8.1.15. Potential Replacement
  • 8.2. Interview 2: Authority from a Company in the Sector (Views Provided Anonymously)
    • 8.2.1. Unmet Needs and Market for Pre-Filled Syringes
    • 8.2.2. Competing Products and Alternatives to Pre-Filled Syringes
    • 8.2.3. Disadvantages and Drawbacks with Pre-Filled Syringes and Related Devices
    • 8.2.4. Pre-Filled Syringe Products, Safety and Vaccines
    • 8.2.5. Challenges for Complex Biological Therapeutics in Pre-Filled Syringes
    • 8.2.6. Versatility of Pre-Filled Syringes
    • 8.2.7. Dual-Chamber Pre-Filled Syringe Systems
    • 8.2.8. Syringe Material: Glass vs. Plastic
    • 8.2.9. Future Developments in Pre-Filled Syringe Systems
    • 8.2.10. Progress in Needle Stick Injury (NSI) Legislation for Europe
    • 8.2.11. NSI Legislation and Implications for Stakeholders
  • 8.3. Interview 3: Dr Marja van der Heijden, Pharmaceutical Formulations Scientist, Abbott Healthcare Products B.V., Weesp, Netherlands
    • 8.3.1. The Main Unmet Needs
    • 8.3.2. Research and Development
    • 8.3.3. Research Challenges Facing Pre-Filled Syringe Technology
    • 8.3.4. Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery
    • 8.3.5. Drawbacks of Pre-Filled Syringes
    • 8.3.6. Technologies, Developments and R&D

9. Conclusions from Our Research and Analyses

  • 9.1. Introduction
  • 9.2. Leading Players in the Market
  • 9.3. Commercial Drivers of the Pre-Filled Syringe Market
  • 9.4. Future Outlook
    • 9.4.1. Further Advances?
    • 9.4.2. Future Developments in Pre-Filled Syringe Systems
  • 9.5. Concluding Remarks

List of Tables

  • Table 2.1. Summary of Drivers for Growth in the Pre-Filled Syringes Market, 2011
  • Table 2.2. Historical Timeline for Development of Syringe Technology
  • Table 2.3. Components for Pre-Fillable Syringes
  • Table 2.4. Leading Brands of Insulin in Pen Syringe Format, 2010
  • Table 2.5. Main Factors Increasing the Interest in Auto-Injectors, 2011
  • Table 3.1. Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015
  • Table 3.2. Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021
  • Table 3.3. Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015
  • Table 3.4. Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021
  • Table 3.5. Other Pre-Filled Syringes: World Sales Forecast, 2010-2015
  • Table 3.6. Other Pre-Filled Syringes: World Sales Forecast, 2016-2021
  • Table 3.7. Total Pre-Filled Syringes: World Sales Forecast, 2010-2015
  • Table 3.8. Total Pre-Filled Syringes: World Sales Forecast, 2016-2021
  • Table 3.9. Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2010-2015
  • Table 3.10. Worldwide Pre-Filled Syringes Market: Sales Forecasts, 2016-2021
  • Table 3.11. Leading Pre-Filled Syringe National Market Forecasts, 2010-2021
  • Table 4.1. Leading Product Classes Driving the Pre-Filled Syringes Market, 2010
  • Table 4.2. List of Some Currently Marketed Monoclonal Antibodies, 2011
  • Table 4.3. Monoclonal Antibodies Market: World Sales Forecast, 2010-2015
  • Table 4.4. Monoclonal Antibodies Market: World Sales Forecast, 2016-2021
  • Table 4.5. Insulins Market: World Sales Forecast, 2010-2015
  • Table 4.6. Insulins Market: World Sales Forecast, 2016-2021
  • Table 4.7. Erythropoietins Market: World Sales Forecast, 2010-2015
  • Table 4.8. Erythropoietins Market: World Sales Forecast, 2016-2021
  • Table 4.9. List of Some Currently Marketed Interferon Drugs, 2011
  • Table 4.10. Interferons Market: World Sales Forecast, 2010-2015
  • Table 4.11. Interferons Market: World Sales Forecast, 2016-2021
  • Table 4.12. G-CSF Market: World Sales Forecast, 2010-2015
  • Table 4.13. G-CSF Market: World Sales Forecast, 2016-2021
  • Table 4.14. List of Some Currently Marketed Recombinant Coagulation Factors, 2011
  • Table 4.15. Recombinant Coagulations Factors Market: World Sales Forecast, 2010-2015
  • Table 4.16. Recombinant Coagulations Factors Market: World Sales Forecast, 2016-2021
  • Table 4.17. List of Some Marketed Human Growth Hormones, 2011
  • Table 4.18. List of Some Currently Marketed Pre-Filled Immunosuppressants Products, 2011
  • Table 4.19. Other Therapeutic Proteins Market: World Sales Forecast, 2010-2015
  • Table 4.20. Other Therapeutic Proteins Market: World Sales Forecast, 2016-2021
  • Table 4.21. List of Some Currently Marketed Biosimilar Drugs, 2011
  • Table 4.22. Biosimilars Market: World Sales Forecast, 2010-2015
  • Table 4.23. Biosimilars Market: World Sales Forecast, 2016-2021
  • Table 4.24. List of Some Currently Marketed Vaccines, 2011
  • Table 4.25. Total Vaccines Market: World Sales Forecast, 2010-2015
  • Table 4.26. Total Vaccines Market: World Sales Forecast, 2016-2021
  • Table 5.1. Anti-Diabetic Agents Available in Pre-Filled Syringe Format, 2011
  • Table 5.2. Lantus: World Sales Forecast, 2010-2015
  • Table 5.3. Lantus: World Sales Forecast, 2016-2021
  • Table 5.4. Humalog: World Sales Forecast, 2010-2015
  • Table 5.5. Humalog: World Sales Forecast, 2016-2021
  • Table 5.6. Novorapid: World Sales Forecast, 2010-2015
  • Table 5.7. Novorapid: World Sales Forecast, 2016-2021
  • Table 5.8. NovoMix/NovoLog: World Sales Forecast, 2010-2015
  • Table 5.9. NovoMix/NovoLog: World Sales Forecast, 2016-2021
  • Table 5.10. Levemir: World Sales Forecast, 2010-2015
  • Table 5.11. Levemir: World Sales Forecast, 2016-2021
  • Table 5.12. Actraphane HM: World Sales Forecast, 2010-2015
  • Table 5.13. Actraphane HM: World Sales Forecast, 2016-2021
  • Table 5.14. Byetta: World Sales Forecast, 2010-2015
  • Table 5.15. Byetta: World Sales Forecast, 2016-2021
  • Table 5.16. Humira: World Sales Forecast, 2010-2015
  • Table 5.17. Humira: World Sales Forecast, 2016-2021
  • Table 5.18. Enbrel: World Sales Forecast, 2010-2015
  • Table 5.19. Enbrel: World Sales Forecast, 2016-2021
  • Table 5.20. Neulasta: World Sales Forecast, 2010-2015
  • Table 5.21. Neulasta: World Sales Forecast, 2016-2021
  • Table 5.22. Avonex: World Sales Forecast, 2010-2015
  • Table 5.23. Avonex: World Sales Forecast, 2016-2021
  • Table 5.24. Rebif: World Sales Forecast, 2010-2015
  • Table 5.25. Rebif: World Sales Forecast, 2016-2021
  • Table 5.26. Some Leading Pre-Filled Syringe Vaccine Products on Market, 2011
  • Table 6.1. Leading Companies in Pre-Filled Syringes Market, 2011
  • Table 7.1. SWOT Analysis of World Pre-Filled Syringes Market: Strengths, 2010-2021
  • Table 7.2. SWOT Analysis of World Pre-Filled Syringes Market: Weaknesses, 2010-2021
  • Table 7.3. SWOT Analysis of World Pre-Filled Syringes Market: Opportunities and Threats, 2010-2021
  • Table 7.4. Risk of Infection Following Needle Stick Incident, 2011
  • Table 7.5. Examples of Leachables Impacting on Safety and Product Quality
  • Table 9.1. Pre-Filled Syringes: World Unit Sales Forecast, 2010, 2012, 2015, 2017, 2019 and 2021
  • Table 9.2. Pre-Filled Syringes: World Sales Forecasts, 2010, 2012, 2015, 2017, 2019 and 2021

List of Figures

  • Figure 3.1. Pre-Filled Syringes: World Unit Sales Forecast, 2010-2015
  • Figure 3.2. Pre-Filled Syringes: World Unit Sales Forecast, 2016-2021
  • Figure 3.3. Pen Systems and Autoinjectors: World Sales Forecast, 2010-2015
  • Figure 3.4. Pen Systems and Autoinjectors: World Sales Forecast, 2016-2021
  • Figure 3.5. Other Pre-Filled Syringes: World Sales Forecast, 2010-2015
  • Figure 3.6. Other Pre-Filled Syringes: World Sales Forecast, 2016-2021
  • Figure 3.7. Total Pre-Filled Syringes Market: World Sales Forecast, 2010-2015
  • Figure 3.8. Total Pre-Filled Syringes Market: World Sales Forecast, 2016-2021
  • Figure 3.9. US and Other Leading Pre-Filled Syringe Market Forecasts, 2010-2021
  • Figure 3.10. Leading National Pre-Filled Syringe Market Forecasts (Lower Range), 2010-2021
  • Figure 3.11. Pre-Filled Syringe Sales in Leading National Markets, 2010
  • Figure 3.12. Pre-Filled Syringe Sales in Leading National Markets, 2015
  • Figure 3.13. Pre-Filled Syringe Sales in Leading National Markets, 2018
  • Figure 3.14. Pre-Filled Syringe Sales in Leading National Markets, 2021
  • Figure 4.1. Monoclonal Antibodies Market: World Sales Forecast, 2010-2021
  • Figure 4.2. Insulins Market: World Sales Forecast, 2010-2021
  • Figure 4.3. Erythropoietins Market: World Sales Forecast, 2010-2021
  • Figure 4.4. Interferons Market: World Sales Forecast, 2010-2021
  • Figure 4.5. G-CSF Market: World Sales Forecast, 2010-2021
  • Figure 4.6. Recombinant Coagulation Factors Market: World Sales Forecast, 2010-2021
  • Figure 4.7. Other Therapeutic Proteins Market: World Sales Forecast, 2010-2021
  • Figure 4.8. Biosimilars Market: World Sales Forecast, 2010-2021
  • Figure 4.9. Vaccines Market: World Sales Forecast, 2010-2021
  • Figure 5.1. Lantus: World Sales Forecast, 2010-2021
  • Figure 5.2. Humalog: World Sales Forecast, 2010-2021
  • Figure 5.3. Novorapid: World Sales Forecast, 2010-2021
  • Figure 5.4. NovoMix/NovoLog: World Sales Forecast, 2010-2021
  • Figure 5.5. Levemir: World Sales Forecast, 2010-2021
  • Figure 5.6. Actraphane HM: World Sales Forecast, 2010-2021
  • Figure 5.7. Byetta: World Sales Forecast, 2010-2021
  • Figure 5.8. Humira: World Sales Forecast, 2010-2021
  • Figure 5.9. Enbrel: World Sales Forecast, 2010-2021
  • Figure 5.10. Neulasta: World Sales Forecast, 2010-2021
  • Figure 5.11. Avonex: World Sales Forecast, 2010-2021
  • Figure 5.12. Rebif: World Sales Forecast, 2010-2021
  • Figure 6.1. BD Medical Sales Revenues: Fiscal Year, 2010
  • Figure 6.2. SCHOTT Sales Revenues by Region, 2009-2010
  • Figure 6.3. Abbott' s Net Sales Worldwide, 2007-2010
  • Figure 6.4. Distribution of Gerresheimer Workforce, 2010-2011
  • Figure 6.5. Gerresheimer Sales by Division, 2010
  • Figure 6.6. Gerresheimer Sales by Region, 2010
  • Figure 7.1. Preference for Pre-Filled Syringes by Healthcare Professionals, 1995-1999
  • Figure 7.2. Pattern of Sharps Injury to Healthcare Workers, 1995-1999
  • Figure 9.1. Pre-Filled Syringes: World Revenue and Unit Sales Forecast, 2010-2021

Companies Listed

  • Abbott Laboratories
  • Albert David
  • Alkermes
  • Alshifa Medical Syringes Manufacturing Company
  • Althea Technologies
  • Amgen
  • Amylin Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Avitro
  • B. Braun Medical
  • Battelle Medical Device Solutions
  • Baxter International
  • Bayer
  • BD Biosciences
  • BD Healthcare Consulting & Services (BDHCS)
  • BD Pharmaceutical Systems
  • Becton, Dickinson and Company
  • Berna Biotech
  • Biogen Idec
  • Bioject Medical Technologies
  • Biopartners
  • Boston Scientific Corp.
  • C. R. Bard.
  • Cambridge Antibody Technology (now a part of AstraZeneca)
  • Cambridge Consultants
  • Catalent Pharma Solutions
  • Centers for Disease Control and Prevention (CDC) [US]
  • Centocor Ortho Biotech
  • Chugai Pharmaceutical (a subsidiary of Roche Holding AG.)
  • Coeur
  • Covidien
  • CSL Behring
  • CSL Biotherapies
  • CT Arzneimettel
  • Daikyo Seiko
  • Disetronic Group
  • Disetronic Holding
  • Dong-A
  • Dongbao
  • Eisai
  • Eli Lilly
  • E. R. Squibb & Sons
  • European Medicines Agency (EMEA/EMA)
  • European Society for Medical Oncology
  • Flamel Technologies
  • Food and Drug Administration (FDA) [US]
  • Gate Pharmaceuticals
  • Genentech
  • GeneScience Pharmaceutical Co.
  • Genzyme
  • Gerresheimer
  • GlaxoSmithKline
  • Henke-Sass Wolf
  • Hindustan Syringes and Medical Devices
  • Hi-Tech Medical Products
  • Hospira
  • Human Genome Sciences
  • Hyaluron Contract Manufacturing
  • Immunex
  • Insulet Corp
  • International Medication Systems
  • Johnson & Johnson
  • LG Life Sciences
  • Life-Shield Products
  • Medex
  • Merck & Co.
  • Merck Serono
  • Merit Medical Systems
  • MG Sterile Products
  • MGlas
  • Milestone Scientific
  • Ministry for Health, Labor and Welfare [Japan]
  • National Health Service (NHS) [UK]
  • Novartis
  • Novo Nordisk
  • Nycomed
  • Occupational Safety and Health Administration (OSHA) [US]
  • Organon Teknika
  • Otsuka Pharmaceutical
  • Owen Mumford
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Plas-Pak Industries
  • PRC State Food and Drug Administration [China]
  • Protalix Biotherapeutics
  • Ratiopharm
  • Retractable Technologies
  • Revolutions Medical Corporation
  • Roche
  • Royal College of Nursing (RCN) [UK]
  • Safety Syringes
  • Sandoz
  • Sanofi Pasteur
  • Sanofi (previously sanofi-aventis)
  • Schering-Plough
  • SCHOTT
  • Shanghai Celgen Bio-Pharmaceutical Co.
  • Simponi
  • Smiths Medical International
  • Specialised Health Products International
  • Star Syringe
  • State Food and Drug Administration [China]
  • Takeda Pharmaceutical Company
  • Talecris Biotherapeutics
  • Terumo Medical Corporation
  • Teva Pharmaceutical Industries
  • The Research Foundation for Microbial Diseases of Osaka University (BIKEN)
  • Tonghua Dongbao Pharmaceutical Co.
  • UCB
  • UltiMed
  • Unilife Medical Solutions
  • Vetter Pharma International
  • Vetter Pharma-Fertigung
  • Vita Needle Company
  • West Pharmaceutical Services
  • World Health Organization (WHO)
  • Wuxi Yushou Medical Appliances Co.
  • Wyeth (now part of Pfizer)
  • Ypsomed
Back to Top